| lisdexamfetamine / Generic mfg. |
NCT00557011: NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD |
|
|
| Completed | 2 | 52 | US | NRP104, lisdexamfetamine dimesylate, Adderall XR, mixed salts of a single-entity amphetamine, Placebo | New River Pharmaceuticals | Attention Deficit Disorder With Hyperactivity | | 12/04 | | |
NCT00247572: Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories |
|
|
| Completed | 2 | 12 | US | NRP104 | New River Pharmaceuticals | Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders | | 11/05 | | |
NCT00905424: Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant |
|
|
| Completed | 2 | 246 | US | Antidepressant + SPD489 (lisdexamfetamine dimesylate), LDX, Vyvanse, Antidepressant + placebo | Shire | Major Depressive Disorder | 08/10 | 08/10 | | |
NCT00922272: Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms |
|
|
| Completed | 2 | 92 | US | SPD489 (lisdexamfetamine dimesylate), Vyvanse, Placebo matching SPD489 (lisdexamfetamine dimesylate) | Shire | Schizophrenia and Predominant Negative Symptoms | 01/11 | 01/11 | | |
NCT00985725: SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder |
|
|
| Completed | 2 | 143 | US | SPD489 (Lisdexamfetamine dimesylate), Vyvanse, Matching placebo | Shire | Major Depressive Disorder | 04/11 | 04/11 | | |
NCT01615887: Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis |
|
|
| Completed | 2 | 63 | US | lisdexamfetamine sulfate, Vyvanse, placebo | State University of New York at Buffalo | Multiple Sclerosis | 08/11 | 08/11 | | |
BED, NCT01291173: Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder |
|
|
| Completed | 2 | 271 | US | lisdexamfetamine dimesylate (SPD489), LDX, Vyvanse, Placebo | Shire | Binge Eating Disorder | 01/12 | 01/12 | | |
| Completed | 2 | 1197 | Europe, US, RoW | Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Vyvanse, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo | Shire | Major Depressive Disorder | 01/14 | 01/14 | | |
NCT02402166: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder |
|
|
| Completed | 2 | 24 | US | SPD489, Lisdexmfetamine dimesylate | Shire | Attention Deficit Hyperactivity Disorder (ADHD) | 06/16 | 06/16 | | |
NCT02659488: Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects |
|
|
| Unknown status | 2 | 40 | US | Lisdexamfetamine, Vyvanse | Lindner Center of HOPE, University of Cincinnati | Binge Eating Disorder | 09/17 | 12/17 | | |
NCT01399827: Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits |
|
|
| Completed | 2 | 2 | US | ADHD Medication, Methylphenidate extended release (OROS-MPH), Concerta, Vyvanse, Dextroamphetamine, Adderall, Mixed Amphetamine Salts, Amphetamine, Strattera, Atomoxetine, Focalin, Dexmethylphenidate, Omega-3 Fatty Acids, Nordic Natural EPA Xtra | Massachusetts General Hospital | Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR) | 11/17 | 11/17 | | |
2017-001490-16: Treatment of Bulimia Nervosa, with and without simultaneous probable ADHD, with the stimulant medicine Lisdexamphetamin . Behandling av Bulimia Nervosa, med och utan samtidig sannolik ADHD, med den psykostimulerande medicinen Lisdexamfetamin. |
|
|
| Ongoing | 2 | 50 | Europe | Capsule, hard, Elvanse vuxen | Stockholms läns landsting, Stiftelsen Söderström-Königska sjukhemmet, Petrus och Augusta Hedlunds stiftelse | Bulimia Nervosa with and without simultaneous Attention Deficit Hyperactivity Disorder. Bulimia Nervosa med och utan samtidig Attention Deficit Hyperactivity Disorder., Bulimia Nervosa with and without simultaneous ADHD Bulimia Nervosa med och utan samtidig ADHD, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT02635035: Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT |
|
|
| Completed | 2 | 38 | US | Lisdexamfetamine, Vyvanse, Placebo | NYU Langone Health, Shire | Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder | 01/19 | 01/19 | | |
2022-001906-24: LAMAinDiab - comparison of 2 pharmacological therapies (lisdexamphetamine vs methylphenidate) for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial LAMAinDiab – porównanie 2 terapii farmakologicznych (lisdeksamfetamina vs metylfenidat) dla pacjentów pediatrycznych z zespołem ADHD i cukrzycą typu 1 - randomizowane krzyżowe badanie kliniczne . |
|
|
| Not yet recruiting | 2 | 150 | Europe | Elvanse, Concerta, Capsule, hard, Prolonged-release tablet | Medical University in Lodz, Agencja Badań Medycznych | Patients with ADHD and type I diabetes. Pacjenci z ADHD i Cukrzycą typu I., Patients with ADHD and type I diabetes. Pacjenci z ADHD i Cukrzycą typu I., Not possible to specify | | | | |
NCT05854667: Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users |
|
|
| Recruiting | 2 | 440 | Canada | Treatment as Usual plus Placebo, Contingency Management, Treatment as Usual plus Placebo plus Contingency Management, Treatment as Usual plus lisdexamfetamine (LDX-01), Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management | Centre hospitalier de l'Université de Montréal (CHUM), Canadian Institutes of Health Research (CIHR) | Methamphetamine Abuse, Methamphetamine-dependence, Addiction, Substance, Addiction | 11/25 | 11/25 | | |
| Not yet recruiting | 2 | 150 | NA | parental training in behavior management, PT training, Lisdexamfetamine, LDX, Methylphenidate, MPH | Medical University of Lodz, Medical University of Silesia, Medical University of Gdansk, Institute of Medical Sciences of the University of Opole, Pediatric Center of the Central Clinical Hospital of the Medical University of Lodz | Attention Deficit Disorder With Hyperactivity, Diabetes Mellitus, Type 1 | 12/27 | 12/27 | | |
NCT00248092: Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse |
|
|
| Completed | 1/2 | 36 | US | NRP104 | New River Pharmaceuticals | Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders | | 05/06 | | |
NCT00573859: The Reinforcing Mechanisms of Smoking in Adult ADHD |
|
|
| Completed | 1/2 | 27 | US | ADHD medication, Dextroamphetamine, Amphetamine mixed salts, Atomoxetine, O-Methylphenidate, Lisdexamfetamine, Placebo | University of California, Irvine | ADHD | 06/10 | 06/10 | | |
